Target intelligence / Profile preview

Eosinophil peroxidase (EPO)

Target
EPO
Molecular classification
Enzyme, Heme peroxidase, Oxidoreductase
01

Overview

Eosinophil peroxidase is a highly cationic, α-helical heme enzyme composed of a heavy and light chain, derived by proteolytic processing from a single precursor protein. It catalyzes the formation of reactive hypohalous acids (especially from bromide and iodide) using hydrogen peroxide as an oxidant, which helps kill invading microbes and can contribute to tissue damage in inflammatory diseases. The enzyme is highly expressed in eosinophils—specialized immune cells involved in allergic responses, parasite defense, and certain pathological inflammatory syndromes. Its biochemical properties and structural features closely resemble those of myeloperoxidase but differ enough to support specific functional roles. Eosinophil peroxidase’s activity in redirecting eosinophils' toxic output extracellularly is crucial for antimicrobial defense but also a driver of tissue remodeling and damage seen in asthma and other eosinophil-mediated disorders.

Other names
Eosinophil peroxidaseEPXEPOEPPEosinophil peroxidase preproprotein
02

Mechanism of action

Inhibition of oxidative activity (reducing reactive oxygen species and tissue damage in inflammatory disease contexts). Suppression of halide oxidation, potentially regulating downstream inflammatory or thrombotic signaling.

03

Biological functions

Immune responseDefense against bacteria and parasites (through cytotoxic activity and generation of reactive oxygen species)Regulation of inflammationCatalysis of hypohalous acid formationTyrosine nitration of granule proteins
04

Disease associations

InflammationAsthma (airway remodeling)Tissue damage (especially in allergic and hypereosinophilic syndromes)Thrombosis (via induction of prothrombotic endothelial phenotypes)Infection (antimicrobial defense against bacteria and parasites)
05

Safety considerations

Potential for off-target effects due to high homology with myeloperoxidase (MPO), complicating development of selective inhibitorsSuppression of EPO may impair host defense against parasite and bacterial infectionExcess activity linked to tissue damage in inflammatory conditions such as asthma, allergic reactions, and hypereosinophilic syndrome
06

Interacting drugs

No FDA-approved drugs directly targeting eosinophil peroxidase are currently listed; research is ongoing to develop specific inhibitors due to its pathogenic role in inflammatory diseases
07

Biomarkers

Elevated serum eosinophil peroxidase levels may indicate eosinophil activation in diseases such as asthma, hypereosinophilic syndrome, and some infections

Beyond the preview

Go deeper on Eosinophil peroxidase (EPO).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eosinophil peroxidase (EPO).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call